Clinical Pre-screening Protocol for Ovarian Cancer

Part of paid clinical trials in Tampa, Florida.

Sponsor
Allarity Therapeutics
Study ID
NCT03877796
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Drug Response Predictor® (DRP) — DEVICE
    A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.

Study Details

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

Key Dates

First listed
Mar 18, 2019
Start date
Apr 11, 2019
Status verified
Jul 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Ovarian cancer patients
    with formalin-fixed paraffin-embedded (FFPE) tumor tissue available

Primary Outcome Measure

Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug [ Time Frame: up to 2 years ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Moffitt Cancer CenterTampaFlorida33612
Merry Markham, MD
Emory Winship Cancer InstituteAtlantaGeorgia30322
Nilaab Meer
[email protected]
494-778-1900
Jennifer Scalici, MD (PRINCIPAL_INVESTIGATOR)
University of New Mexico Comprehensive CancerAlbuquerqueNew Mexico87131
Natalie Everett
[email protected]
Amaranta Craig, MD (PRINCIPAL_INVESTIGATOR)
The Blavatnik Family-Chelsea Medical Center at Mount SinaiNew YorkNew York10011
Neha Kumarley
[email protected]
212-824-7859
Stephanie Blank, MD (PRINCIPAL_INVESTIGATOR)
OU Health Stephenson Cancer CenterOklahoma CityOklahoma73104
Christine Pappaterra, RN
[email protected]
405-271-8707
Jacqueline Bohn,, MD (PRINCIPAL_INVESTIGATOR)
University Medical Center Cancer CenterLubbockTexas79415
Mariana Fiori
[email protected]
Mark Reedy, MD (PRINCIPAL_INVESTIGATOR)
Swedish Center for Research and InnovationSeattleWashington98122
Karina Sills
[email protected]
206-386-2227
Fernanda Baptista Musa, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Tampa, FL

Nationwide
Ovarian cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials
By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Moffitt Cancer Center· Tampa, FLEmory Winship Cancer Institute· Atlanta, GAUniversity of New Mexico Comprehensive Cancer· Albuquerque, NMThe Blavatnik Family-Chelsea Medical Center at Mount Sinai· New York, NYOU Health Stephenson Cancer Center· Oklahoma City, OKUniversity Medical Center Cancer Center· Lubbock, TX

Related Studies